menu
Disease Target Structure Research Center
HOME > About KRIBB > Organization > Research Fields > Division of Biomaterials Research > Disease Target Structure Research Center
Introduction
  • Determination of three-dimensional structures of disease targets and development of highly efficient drug discovery platform technology for disease targets.
    • Determination of structures and functions of disease target proteins
    • Development of a drug discovery platform technology for disease targets
    • Proteomics-based discovery and validation of disease targets
    • Animal model-based research for the treatment of degenerative diseases
    • Development of nanopore sensor technology
Research Areas
  • Research on structures and functions of disease target proteins
  • Proteomics-based discovery and validation of disease target proteins
  • Animal model-based research for treatment of degenerative diseases
  • Drug discovery by cellular signaling research
  • Development of nanopore sensor technology for detecting proteins and nucleic acids
  • Nanotoxicity assessment using zebrafish
Head
Investigator
Name Position Tel / Email Detail
Sung Goo Park Associate Director / Detail

Tel

042-860-4262

Email

sgpark@kribb.re.kr

Achievements
  • Elucidation of structures and functions of kinases and phosphatases
  • Determination of structures of apoptosis regulating proteins and development of a structure-based multi-targeting strategy
  • Elucidation of growth-regulating microRNA
  • Development of a novel screening technology for protein-protein interaction inhibitors using nanopores
  • Research for treatment of Alzheimer’s disease using photoactivated porphyrins
  • High-resolution real-time imaging analysis to study the effect of graphene oxide nanoparticles on blood vessel development
  • Discovery of a novel immunomodulatory drug(IMiD) and the its application to PROTAC technology
  • Human disease modeling and identifi cation of drug candidates using zebrafish
Selected Publications
  • Acoustic wave-driven functionalized particles for aptamer-based target biomolecule separation.
    • Anal Chem. 89(24):13313-13319.
    • Tae-Sung Yoon (Co-corresponding)
  • The cellular basis of dendrite pathology in neurodegenerative diseases.
    • BMB Rep. 50(1):5-11.
    • Sunhong Kim (Co-first)
  • RNA activation-independent DNA targeting of the Type III CRISPR-Cas system by a Csm complex.
    • EMBO Rep. 18(5):826-840.
    • Eui-Jeon Woo (Co-corresponding)
  • Two-track virtual screening approach to identify both competitive and allosteric inhibitors of human small C-terminal domain phosphatase 1.
    • J Comput Aided Mol Des. 31(8):743-753.
    • Seung Jun Kim (Co-corresponding)
  • Zebrafish knockout of Down syndrome gene, DYRK1A, shows social impairments relevant to autism.
    • Mol Autism. 8:50.
    • Jeong-Soo Lee (Co-corresponding)
  • Uracil DNA glycosylase (UDG) activities in Bradyrhizobium diazoefficiens : characterization of a new class of UDG with broad substrate specificity.
    • Nucleic Acids Res. 45(10):5863-5876.
    • Eui-Jeon Woo (Co-corresponding)
  • Development of zebrafish medulloblastoma-like PNET model by TALEN-mediated somatic gene inactivation.
    • Oncotarget. 8(33):55280-55297.
    • Jeong-Soo Lee (Co-corresponding)
  • Pharmacological intervention of early neuropathy in neurodegenerative diseases.
    • Pharmacol Res. 119:169-177.
    • Jeong Hoon Kim (Co-first)